patent. Respondents did not oppose the motion.

On April 8, 2026, the presiding ALJ issued the subject ID (Order No. 6) granting pursuant to Commission Rules 210.14(b) and 210.42(c) (19 CFR 210.14(b), 210.42(c)) Complainant's motion to amend the complaint and NOI. The ID finds that good cause exists for amending the complaint and NOI to add claim 9 of the '818 patent because Complainant obtained additional information during discovery that was not previously known to Complainant. The ID also finds that including claim 9 of the '818 patent will not substantially expand the scope of discovery because the '818 patent is already asserted in this investigation, and because Complainant is withdrawing its allegations of infringement as to five other claims.

No party filed a petition for review of the subject ID.

The Commission has determined not to review the subject ID. Accordingly, the complaint and NOI are amended to assert claim 9 of the '818 patent, and to withdraw allegations of infringement as to claim 6 of the '823 patent, claims 6 and 19 of the '818 patent, claim 6 of the '315 patent, and claim 6 of the '067 patent.

The Commission vote for this determination took place on April 29, 2026.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: April 29, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–08576 Filed 5–1–26; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1446]

Certain Active Electrical Cables and Components Thereof; Notice of Commission Determination Not To Review Two Initial Determinations Terminating the Investigation as to the Remaining Respondents Based on Settlement; Termination of the Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review two initial determinations (''IDs'') of the presiding administrative law judge (''ALJ'') that terminate the remaining respondents Molex, LLC (''Molex'') of Lisle, Illinois (Order No. 43) and TE Connectivity Corporation (''TECC'') of Berwyn, Pennsylvania (Order No. 44) from the above-captioned investigation based on settlement. The investigation is terminated as to Molex and TECC and, thus, in its entirety.

FOR FURTHER INFORMATION CONTACT: Richard P. Hadorn, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–3179. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server at *https://www.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on April 18, 2025, based on a complaint filed by Credo Semiconductor Inc. of San Jose, California and Credo Technology Group Ltd. of the Cayman Islands (collectively, ''Credo''). 90 FR 16551–52 (Apr. 18, 2025). The complaint, as amended, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based on the importation into the United States, the sale for importation, and the sale within the United States after importation of certain active electrical cables and components thereof by reason of the infringement of certain claims of U.S. Patent Nos. 10,877,233 (''the '233 patent''), 11,012,252, and 11,032,111. *Id.* The notice of investigation names three respondents: Amphenol Corporation (''Amphenol'') of Wallingford, Connecticut; Molex; and TE Connectivity PLC (''TE PLC'') of Galway, Ireland. *Id.* at 16552. The Office of Unfair Import Investigations (''OUII'') is also named as a party. *Id.*

On June 30, 2025, the Commission amended the complaint and notice of investigation to replace respondent TE PLC with TECC. Order No. 7 (May 28, 2025), *unreviewed by* 90 FR 27876–77 (June 30, 2025).

On September 24, 2025, the Commission terminated the investigation as to respondent Amphenol based on settlement. Order No. 18 (Sept. 5, 2025), *unreviewed by* Comm'n Notice (Sept. 24, 2025).

On December 3, 2025, the Commission terminated the investigation as to the '233 patent based on withdrawal of the complaint. Order No. 21 (Sept. 30, 2025), *unreviewed by* Comm'n Notice (Dec. 3, 2025).

On March 26, 2026, Credo and Molex filed a joint motion to terminate the investigation as to Molex based on a settlement agreement, attaching thereto confidential and public versions of the subject agreement. On April 2, 2026, OUII filed a response in support of the motion. Respondent TECC did not file a response.

On March 26, 2026, Credo and TECC filed a joint motion to terminate the investigation as to TECC based on a settlement agreement, attaching thereto confidential and public versions of the subject agreement. The motion states that respondent Molex does not oppose the motion. On April 3, 2026, OUII filed a response in support of the motion. Respondent Molex did not file a response.

On April 14, 2026, the ALJ issued both subject IDs (Order Nos. 43 and 44). Order Nos. 43 and 44 grant the unopposed motions to terminate the investigation as to Molex and TECC, respectively, finding that the motions comply with the requirements of Commission Rule 210.21(b)(1) (19 CFR 210.21(b)(1)), and that the proposed settlements do not adversely affect the public interest in accordance with Commission Rule 210.50(b)(2) (19 CFR 210.50(b)(2)). Order No. 43 at 2–3; Order No. 44 at 2–3. Order Nos. 43 and 44 further grant the moving parties' requests to limit service of the confidential settlement agreements. Order No. 43 at 3–5; Order No. 44 at 3–5. No petitions for review of the subject IDs were filed.

The Commission has determined not to review the subject IDs. The investigation is hereby terminated as to the remaining respondents Molex and TECC and, thus, in its entirety.

The Commission vote for this determination took place on April 29, 2026.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: April 30, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–08616 Filed 5–1–26; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1708]

Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: ANI Pharmaceuticals Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before June 3, 2026. Such persons may also file a written request for a hearing on the application on or before June 3, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on April 15, 2026, ANI Pharmaceuticals Inc., 70 Lake Drive, East Windsor, New Jersey 08520–5321, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Levorphanol	9220	II
Tapentadol	9780	II

Levorphanol (9220) will be imported for distribution to customers. Tapentadol (9780) will only be used to import small quantities for internal research and reference standards purposes. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Thomas Prevoznik,

Deputy Assistant Administrator.

[FR Doc. 2026–08587 Filed 5–1–26; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1710]

Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Patheon API Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 6, 2026. Such persons may also file a written request for a hearing on the application on or before July 6, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on February 9, 2026, Patheon API Inc., 6173 East Old Marion Highway, Florence, South Carolina 29506, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Dimethyltryptamine	7435	I
Psilocybin	7437	I
Psilocyn	7438	I

The company plans to bulk manufacture the listed controlled substances for research and clinical trials. No other activities for these drug codes are authorized for this registration.

Thomas Prevoznik,

Deputy Assistant Administrator.

[FR Doc. 2026–08588 Filed 5–1–26; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1711]

Bulk Manufacturer of Controlled Substances Application: ANI Pharmaceuticals Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: ANI Pharmaceuticals Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration